UPPSALA, Sweden, May 25 /PRNewswire/ -- Beactica AB, the Swedish fragment-based drug discovery company, today announced that it has entered into an agreement with Cubist Pharmaceuticals, Inc. . Under the agreement, Beactica will use its Sprint(TM) surface plasmon resonance (SPR)-integrated drug discovery platform to target multi-component proteins from pathogenic bacteria of interest to Cubist. Financial terms of the agreement were not disclosed.
"We are pleased to be working with Cubist in their quest to develop next-generation anti-bacterials" said Beactica CEO, Dr Per Kallblad. "Cubist has excellent strengths in the area and it is a source of pride to have been selected to help progress one of their discovery programmes."
Cubist becomes the fifth life-science company to enter an agreement with Beactica in the past eighteen months.
Beactica AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the biophysical interaction of molecules in order to generate novel therapeutics. Beactica's Sprint(TM) drug discovery platform efficiently integrates surface plasmon resonance (SPR) to accelerate the identification of optimal starting points and development routes for lead discovery. The company was spun out of Uppsala University in August 2006. As well as building collaborations with external companies, Beactica is progressing its own drug discovery programmes of small molecule therapeutics. For more information about Beactica, please visit http://www.beactica.com.
CONTACT: For further information, please contact Dr Per Kallblad, CEO